Health
Medical Warning Issued Following Mismanaged Cancer Treatment Case
A Thai specialist has shared a cautionary case study involving a 49-year-old patient whose cancer progressed to stage 4 due to an incorrect chemotherapy regimen.
On August 24, 2026, Dr. Pornchai Ocharoenrat, a specialist in breast and thyroid cancer, published a cautionary case study on his professional social media page. The report details the experience of a 49-year-old woman diagnosed with HER2-enriched breast cancer. Initially, the patient was diagnosed at stage 2B (T2N1M0) with a 3cm tumor in her right breast and lymph node involvement.
According to the report, the patient received a high-cost targeted therapy regimen, specifically Phesgo (a combination of Pertuzumab and Trastuzumab). However, the doctor noted that the accompanying chemotherapy formula was incorrect for her specific condition. This mismatch reportedly led to the cancer progressing to stage 4. The doctor emphasized the importance of precise treatment protocols, noting that while the patient eventually changed her treatment path, the initial error had severe consequences.
For residents and expatriates in Thailand, this case highlights the critical importance of verifying treatment plans and seeking second opinions when dealing with complex medical conditions. It serves as a reminder that even high-cost, advanced medications require precise clinical application to be effective. As this is a single case study shared by a medical professional, it remains to be confirmed how widespread such diagnostic or procedural errors are within the broader healthcare system. Patients are encouraged to maintain open communication with their oncology teams regarding their specific treatment formulas.